Erschienen in:
15.10.2021 | Brief Report
Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro
verfasst von:
Jessica Fernandes Ramos, Gleice Leite, Roberta Cristina Ruedas Martins, Camila Rizek, Sabri Saeed Al Sanabani, Flavia Rossi, Thais Guimarães, Anna Sara Levin, Vanderson Rocha, Silvia Figueiredo Costa
Erschienen in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Ausgabe 2/2022
Einloggen, um Zugang zu erhalten
Abstract
Bloodstream infection (BSI) caused by carbapenem-resistant P. aeruginosa (CRPA) has high mortality in hematopoietic stem cell transplant (HSCT) recipients. We performed MIC, checkerboard, time-kill assay, PFGE, PCR, and whole genome sequence and described the clinical outcome through Epi Info comparing the antimicrobial combination in vitro. Mortality was higher in BSI caused by CRPA carrying the lasB virulence gene. The isolates were 97% resistant to meropenem displaying synergistic effect to 57% in combination with colistin. Seventy-three percent of the isolates harbored blaSPM-1 and Tn4371 and belonged to ST277. The synergistic effect in vitro with meropenem with colistin appeared to be a better therapeutic option.